Last $1.60 USD
Change Today 0.00 / 0.00%
Volume 159.2K
RXII On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
NASDAQ CM
Frankfurt
As of 5:20 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

rxi pharmaceuticals (RXII) Snapshot

Open
$1.60
Previous Close
$1.60
Day High
$1.62
Day Low
$1.59
52 Week High
02/24/14 - $6.84
52 Week Low
12/23/14 - $1.40
Market Cap
33.8M
Average Volume 10 Days
348.6K
EPS TTM
$-2.09
Shares Outstanding
21.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RXI PHARMACEUTICALS (RXII)

Related News

No related news articles were found.

rxi pharmaceuticals (RXII) Related Businessweek News

No Related Businessweek News Found

rxi pharmaceuticals (RXII) Details

RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering, developing, and commercializing therapies based on its proprietary, next-generation RNA interference (RNAi) platform. The company’s lead product candidate, RXI-109, is a self-delivering RNAi compound, which is in Phase II clinical trial for use in the reduction of dermal scarring. Its therapeutic development programs in the discovery and preclinical stages include products for the treatment of ocular scarring, liver fibrosis, joint fibrosis, and vascular restenosis. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

12 Employees
Last Reported Date: 03/28/14
Founded in 2011

rxi pharmaceuticals (RXII) Top Compensated Officers

Chief Executive Officer, President, Acting Ch...
Total Annual Compensation: $368.1K
Chief Development Officer
Total Annual Compensation: $324.4K
Compensation as of Fiscal Year 2013.

rxi pharmaceuticals (RXII) Key Developments

RXi Pharmaceuticals Corporation Enters into an Assignment and Exclusive Global License Agreement with Hapten Pharmaceuticals, LLC

RXi Pharmaceuticals Corporation announced that it has entered into an assignment and exclusive global license agreement with Hapten Pharmaceuticals, LLC for the therapeutic use of Samcyprone. Samcyprone is a proprietary gel formulation of diphenylcyclopropenone (DPCP), an immunomodulating agent that works by initiating a T-cell response. Although DPCP is not a registered drug, it is used successfully by dermatologists as a topical immunomodulator to treat dermatological diseases. Samcyprone is expected to demonstrate an improved safety and use profile over DPCP as currently applied. A Phase 2a trial to evaluate the efficacy and safety of Samcyprone for the treatment of viral warts has been completed and Phase 2a trials for the treatment of cutaneous metastases of various cancers including melanoma and for the treatment of alopecia areata are underway. Under the terms of the Agreement, Hapten will sell and assign to RXi certain patent rights and related assets and rights to Samcyprone. The Agreement will become effective at a closing that is scheduled to occur in early 2015 and which is subject to the satisfaction of certain closing conditions. Once the Agreement is effective, Hapten will receive an upfront payment payable in cash and common stock, will be entitled to receive future milestone payments tied to the achievement of certain clinical and commercial objectives and will receive royalties based on product sales.

RXi Pharmaceuticals Corporation Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

RXi Pharmaceuticals Corporation reported unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company's total revenues were $16,000 compared to $92,000 a year ago. Loss from operations was $2,209,000 compared to $2,071,000 a year ago. Net loss was $2,206,000 compared to $2,059,000 a year ago. The decrease in net loss of $11.9 million was primarily attributable to a one-time charge of $12.3 million in the first quarter of 2013 related to the fair value of common shares issued to OPKO for the purchase of substantially all of OPKO's RNAi-related assets. Net loss applicable to common stockholders was $2,906,000 or $0.17 per basic and diluted share compared to $3,506,000 or $0.30 per basic and diluted share a year ago. The decrease in net loss applicable to common stockholders of $15.6 million was primarily attributable to the aforementioned decrease in net loss as compared to the prior year and a decrease of $3.7 million in the fair value of dividends paid on preferred stock to the Company's preferred shareholders. For the nine months, the company's total revenues were $57,000 compared to $370,000 a year ago. Loss from operations was $6,520,000 compared to $18,431,000 a year ago. Net loss was $6,496,000 compared to $18,417,000 a year ago. Net loss applicable to common stockholders was $10,164,000 or $0.69 per basic and diluted share compared to $25,810,000 or $2.64 per basic and diluted share a year ago. The decrease in net loss applicable to common stockholders of $15.6 million was primarily attributable to the aforementioned decrease in net loss as compared to the prior year and a decrease of $3.7 million in the fair value of dividends paid on preferred stock to the Company's preferred shareholders.

RXi Pharmaceuticals Corporation Presents at EBD Group's Biopharm America 2014 Conference, Sep-24-2014 11:20 AM

RXi Pharmaceuticals Corporation Presents at EBD Group's Biopharm America 2014 Conference, Sep-24-2014 11:20 AM. Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States. Speakers: Geert Cauwenbergh, Chief Executive Officer, President, Acting Chief Financial Officer, Director and Member of Corporate Governance Committee.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RXII:US $1.60 USD 0.00

RXII Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RXII.
View Industry Companies
 

Industry Analysis

RXII

Industry Average

Valuation RXII Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 325.5x
Price/Book 11.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 195.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RXI PHARMACEUTICALS, please visit www.rxipharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.